MedTrace Logo

Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.

NCT01397994 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-12-08

No results posted yet for this study

Summary

This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.

Conditions

  • Chronic Stable Angina

Interventions

DRUG

Nicorandil

Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1

DRUG

Atenolol

Patients in the control arm would be advised atenolol 50 mg od

Sponsors & Collaborators

  • Ferozsons Laboratories Ltd.

    lead INDUSTRY

Principal Investigators

  • Tariq Ashraf, MBBS,FCPS,FACC,FSCAI · National Institute of Cardiovascular Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01397994 on ClinicalTrials.gov